# The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer

Study · id `cardio:ct-nct06861088` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06861088](<https://clinicaltrials.gov/study/NCT06861088>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT06861088

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 480 participants.

## Technical summary

Registry record NCT06861088. Randomized; quadruple masking; primary purpose prevention. Start 2025-12-19 (actual); primary completion 2027-10-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase: Phase 3
- Enrolled: 480 participants (planned count; ClinicalTrials.gov record NCT06861088, source copy `cardio:ctgov-nct06861088-2026-02-02`, retrieved 2026-10-31)
- Started: 2025-12-19 (actual) (ClinicalTrials.gov record NCT06861088, source copy `cardio:ctgov-nct06861088-2026-02-02`, retrieved 2026-10-31)
- Primary completion: 2027-10-31 (anticipated) (ClinicalTrials.gov record NCT06861088, source copy `cardio:ctgov-nct06861088-2026-02-02`, retrieved 2026-10-31)
- Completion: 2029-10-31 (anticipated) (ClinicalTrials.gov record NCT06861088, source copy `cardio:ctgov-nct06861088-2026-02-02`, retrieved 2026-10-31)
- Countries: United States (ClinicalTrials.gov record NCT06861088, source copy `cardio:ctgov-nct06861088-2026-02-02`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06861088-2026-02-02`, retrieved 2026-10-31)

## The registry's words

- Brief title: The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer
- Acronym: CATIQ P3
- Condition: Venous Thromboembolism
- Condition: Metastatic Pancreatic Cancer
- Condition: Locally Advanced Pancreatic Adenocarcinoma
- Intervention (Drug): Kinisoquin™
- Intervention (Drug): Placebo
- Lead sponsor: Quercis Pharma AG
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Deep vein thrombosis (`cardio:deep-vein-thrombosis`)
- Registry condition terms include this condition: Pulmonary embolism (`cardio:pulmonary-embolism`)

## Provenance

Content hash: cb8a860bc201c9179905d88b0624cfd7c86f274df6c4de3dd16d210774f485a2
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
